Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/KCT0003759
KCT0003759Active, not recruiting未知

A Multicenter, Subject-blinded, Randomized Study to Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent in Patients Undergoing Drug-eluting Stent Procedure after Coronary Angiography

CGBio0 sites118 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Active, not recruiting
Sponsor
Enrollment
118
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
20(Year) to 79(Year) (—)
Sex
All

Inclusion Criteria

  • •1. Subjects with significant coronary artery stenosis (> 50% diameter stenosis on coronary angiography)
  • •2. Subjects with stable angina, unstable angina, asymptomatic myocardial ischemia, and non-ST-elevated myocardial infarction (NSTEMI)
  • •3. Subjects eligible for coronary stenting
  • •4. Subjects with a lesion length of less than 40 mm and a coronary artery diameter of greater than or equal to 2.25 mm and less than 4.0 mm on the coronary angiography screening at the screening stage (except for lesions not covered by the procedure)
  • •5. Subjects with satisfactory TIMI (thrombolysis in myocardial infarction) flow grade 1 or higher on the coronary angiogram
  • •6. Subjects who could use up to two stents (CGBIO stent: length 38 mm or less, control group: BioMatrix length 36 mm or less)
  • •7. One-vessel percutaneous coronary intervention (PCI)
  • •* Includes 2VD or 3VD patient or even one target lesion
  • •8. Subjects aged 20 years or older and younger than 80 years
  • •9. Those who voluntarily agreed to participate in this trial and provided written consent

Exclusion Criteria

  • •1. Subjects with acute myocardial infarction [acute Q-wave myocardial infarction (STEMI) within 72 hours]
  • •2. Subjects experiencing cardiogenic shock
  • •3. Subjects with chronic total occlusion
  • •4. Subjects with restenosis lesion
  • •5. Subjects with a left main canal lesion
  • •6. Subjects with graft vessel lesions
  • •7. Subjects with systemic bleeding disorder, coagulation disorder
  • •8. Subjects with expected life expectancy within 1 year due to accompanying disease
  • •9. Subjects with contraindications to Aspirin, Clopidogrel, Heparin, Sirolimus, Biolimus A9
  • •10. Patients who have been treated with Drug-eluting stent (DES) or Drug-eluting balloon (DEB) containing Sirolimus, Paclitaxel, or Biolimus A9 within 12 months prior to clinical study or who have been treated with Bare-metal stent (BMS)
  • •11. Pregnant women, lactating women, women who do not consent to the appropriate use of contraception during the trial
  • •- Proper contraceptive methods: Infertility surgery, hormonal contraceptive methods (subcutaneous implants, injections, oral contraceptives, etc.), intrauterine devices (copper loop, hormone containing intrauterine system)
  • •12. Platelets (100 103 / µL), Platelets (700 103 / µL), AST and ALT> 5.0 x ULN (WBC < , Creatinine> 2.0 mg / dL
  • •13. Those who have had intracranial bleeding within 6 months before participating in the clinical trial
  • •14. Subjects with or without medical conditions, such as cardiovascular, digestive, respiratory, endocrine, and central nervous system disorders, such as mental illness,
  • •15. Patients with autoimmune disease (such as systemic lupus erythematosus) who are receiving oral or intravenous immunosuppressant therapy or those with acquired immunodeficiency
  • •16. Those who have participated in other clinical trials within four weeks prior to screening and have been or are currently participating in a drug or medical device (provided that they have participated in observational studies that do not involve treatment or treatment and maintain the concomitant therapy permitted in this trial Can participate regardless of termination of the clinical trial.)
  • •17. Any other person deemed inappropriate by the tester

Investigators

Sponsor
CGBio

Similar Trials

Completed
Phase 3
A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisonemyasthenia gravismyasthenia1000381610028302
NL-OMON30649ational Institute of Health5
Active, not recruiting
Not Applicable
A Multicenter, Double-blind, Randomized Study comparing the Safety and Tolerability of Iloprost inhalation solution delivered by I-neb utilizing Power disc-15 and Power disc-6 in Patients with Symptomatic Pulmonary Arterial Hypertension - PROWESS 15 Extensio
EUCTR2009-011013-24-ATActelion Pharmaceuticals Ltd.63
Unknown
Phase 3
A Randomized, Double-blinded, Multicenter Study of Denosumab Compared With Zoledronic acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Breast CancerAdvanced breast cancer with bone metastases
JPRN-jRCT2080220875DAIICHISANKYO Co.,Ltd.1,960
Active, not recruiting
Not Applicable
A Randomized, Double-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of One Dose of Four FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccines Containing 3.5µgHA, 6µgHA, 9µgHA or 15 µgHA of Seasonal A/H1N1, A/H3N2 and B Influenza Antigens in Non-elderly Adult and Elderly SubjectsImmunization of healthy people against influenza virus infectionMedDRA version: 14.0Level: LLTClassification code 10059430Term: Influenza immunizationSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2011-003166-32-HUOmninvest Ltd.
Completed
Phase 2
A study of the safety and efficacy of LBS-020 in patients with mouth dryness following radiotherapyOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonCancer - Head and neckXerostomia
ACTRN12619000593134ubris LLC37